AT:GTG Genetic Technologies

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company has a research and service agreement with The University of Melbourne for the development and enhancement of the BREVAGenplus breast cancer risk assessment test, as well as a strategic alliance with Blockchain Global Limited. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.This company has ADRs that trade in the U.S. as the symbol GENE.

0.00 AUD
As of 03/27/2023

---

Security Information

---

Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Unknown
Industry:  Diagnostics & Research
Index country:  Australia
Country of incorporation:  Australia
IPO date:  01/01/1900
Stock exchange:    Asx - All Markets
Exchange country:   Australia
Market cap:   27,701,910 AUD
Current dividend yield:   0.00%
Sedol: